Pentacyclo Ring System Having The Diazine Ring As One Of The Cyclos Patents (Class 544/342)
-
Publication number: 20110059977Abstract: The present invention relates to the use, for the preparation of a medicament intended for the treatment or the prevention of pathologies linked to, or caused by mycobacteria, of at least one of the compounds of the following formula (I): in which B represents in particular a nitrogen atom, and R1, R2, R3, R4, R5, R6, R7 and R8 represent in particular a hydrogen atom.Type: ApplicationFiled: March 22, 2007Publication date: March 10, 2011Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.)Inventors: Alain Robert Francois Maxime Fournet, Delphine Lagoutte, Erwan Poupon, Flor Soriano-Agaton
-
Publication number: 20110020931Abstract: A proliferation promoting agent for neural stem cells, which comprises a compound produced by Penicillium sp. CND1007 (FERM BP-10917) or a pharmaceutically acceptable salt thereof, as an active ingredient; a novel compound produced by Penicillium sp. CND 1007 or a pharmaceutically acceptable salt thereof; a method for producing neural stem cells, which comprises culturing a neural stem cells to proliferate the neural stem cells in a presence of the compound produced by Penicillium sp. CND 1007 or a pharmaceutically acceptable salt thereof, and harvesting the neural stem cells from the culture; and the like are provided.Type: ApplicationFiled: January 29, 2009Publication date: January 27, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Hideyuki Onodera, Michio Ichimura, Kouji Baba, Tsutomu Agatsuma, Setsuya Sasho, Makoto Suzuki, Susumu Iwamoto, Shingo Kakita
-
Publication number: 20110006287Abstract: A copolymer comprising at least one donor monomer and at least one acceptor monomer is described. The polymer may optionally further comprise, consist or consist essentially of at least one additional comonomer. Various donor monomers, acceptor monomers and additional comonomers are also described. The polymer is useful in the manufacture of microelectronic devices such as optoelectronic devices.Type: ApplicationFiled: March 18, 2010Publication date: January 13, 2011Inventors: Wei You, Shengqiang Xiao
-
Publication number: 20100331325Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.Type: ApplicationFiled: August 5, 2010Publication date: December 30, 2010Inventors: José Maria CID-NÚÑEZ, Antonius Adrianus Hendrikus Petrus MEGENS, Andrés Avelino TRABANCO-SUÁREZ, Mohamed KOUKNI, Georges Joseph Cornelius HOORNAERT, Frans Josef Cornelius COMPERNOLLE, Tomasz KOZLECKI, Hua MAO, Sushil Chandra JHA, Francisco Javier FERNÁNDEZ-GADEA
-
Patent number: 7820838Abstract: An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R2 of N12 site is trichloroethoxycarbonyl (Troc) to which various substituents can be introduced by mild condition, further having 10 members ring structure which can be converted to a ring of other numbered members.Type: GrantFiled: July 24, 2008Date of Patent: October 26, 2010Assignee: Japan Science and Technology AgencyInventors: Tohru Fukuyama, Toshiyuki Kan
-
Patent number: 7807833Abstract: An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R2 of N12 site is trichloroethoxicarbonyl (Troc) to which various substituents can be introduced by mild condition, further having 10 members ring structure which can be converted to a ring of other numbered members.Type: GrantFiled: April 25, 2007Date of Patent: October 5, 2010Assignee: Japan Science and Technology AgencyInventors: Tohru Fukuyama, Toshiyuki Kan
-
Patent number: 7799785Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.Type: GrantFiled: December 6, 2005Date of Patent: September 21, 2010Assignee: Janssen Pharmaceutica NVInventors: José Maria Cid-Núñez, Antonius Andrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Mohamed Koukni, Georges Joseph Cornelius Hoornaert, Frans Josef Cornelius Compernolle, Tomasz Kozlecki, Hua Mao, Sushil Chandra Jha, Francisco Javier Fernández-Gadea
-
Publication number: 20100202984Abstract: Disclosed are naphthalinamidinimide of formula (I), wherein R1, R2, R3, R4, R5 and R6 independently from each other are hydrogen; or C1-C37alkyl; wherein—one to 10 of the CH2 units of C1-C37alkyl independently from each may be substituted by carbonyl groups; oxygen atoms; sulphur atoms; selenium atoms; tellurium atoms; cis- or trans-CH?CH— groups; acetylenic C?C— groups; 1,2-, 1,3- or 1,4-substituted phenyl radicals; 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-disubstituted pyridine radicals; 2,3-, 2,4-, 2,5- or 3,4-disubstituted thiophene radicals; 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 2,3-, 2,6- or 2,7-disubstituted 1,2-, 1,3-, 1,4-, 1,5-, 1,6-, 1,7-, 1,8-, 1,9-, 1,10-, 2,3-, 2,6-, 2,7-, 2,9-, 2,10- or 9,10-disubstituted anthracene radicals; wherein one or 2 CH— groups of the CH?CH— groups, the naphthalene radicals and the anthracene radicals may be substituted by nitrogen atoms; —up to 12 single hydrogen atoms of the CH2— groups independently from each other may be substituted at the same carbon atoms by fluorType: ApplicationFiled: July 21, 2006Publication date: August 12, 2010Inventors: Heinz Langhals, Harald Jaschke, Thomas Ehlis, Olof Wallquist
-
Patent number: 7741325Abstract: A compound selected from those of formula (I): wherein: B1, B2 represent carbon or nitrogen, X, Y, X1 and Y1 represent a group selected from hydrogen, halogen, hydroxy, alkoxy, nitro, cyano, trihaloalkyl and NRaRb wherein Ra and Rb are as defined in the description, R1 represents hydrogen or alkyl, R2 represents a group selected from hydrogen, alkyl, —OR?a, —NR?aR?b, —O-Ta-OR?a, —NR?a-Ta-NR?aR?b, NR?a—C(O)-TaH, —O—C(O)-TaH, —O-Ta-NRa?Rb?, —NR?a-Ta-OR?a, —NR?a-Ta-CO2R?a and —NR?a—C(O)-Ta-NR?aR?b wherein R?a, R?b, R?a and Ta are as defined in the description, R3, R4 represent hydrogen or alkyl, A represents a group of formula —CH(R5)—CH(R6)—, —CH?C(R7)—, —C(R7)?CH—, —C(O)—CH(R8)— or —CH(R8)—C(O)— wherein R5, R6, R7 and R8 are as defined in the description, its isomers, N-oxides, and addition salts thereof with a pharmaceutically acceptable acid or base, and medicinal products containing the same which are useful in the treatment of cancer.Type: GrantFiled: January 31, 2005Date of Patent: June 22, 2010Inventors: Michel Koch, François Tillequin, Sylvie Michel, John Hickman, Alain Pierre, Stéphane Leonce, Bruno Pfeiffer, Pierre Renard
-
Patent number: 7736707Abstract: The present invention provides a birefringent film that hardly generates cracks even when the film is exposed under a high-temperature and high-humidity environment for a long period of time. The birefringent film of the present invention is a film containing, as a major component, a lyotropic liquid crystalline polycyclic compound containing an acenaphtho[1,2-b]quinoxaline derivative unit in a molecular structure and having a molecular weight of 500 or higher. The birefringent film of the present invention preferably has a refractive index ellipsoid showing a relationship of nx?nz>ny, and more preferably has an in-plane birefringence of 0.01 or higher at the wavelength of 590 nm.Type: GrantFiled: March 17, 2008Date of Patent: June 15, 2010Assignee: Nitto Denko CorporationInventors: Shoichi Matsuda, Junzo Miyazaki
-
Publication number: 20100098630Abstract: Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a phenazine or quinoxaline substituent. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides.Type: ApplicationFiled: December 28, 2007Publication date: April 22, 2010Applicant: AMBRX, INC.Inventor: Zhenwei Miao
-
Publication number: 20100075911Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: ApplicationFiled: March 13, 2009Publication date: March 25, 2010Applicant: TETRALOGIC PHARMACEUTICALS CORPORATIONInventors: Stephen M. CONDON, Matthew G. LaPORTE, Yijun DENG, Susan R. RIPPIN
-
Publication number: 20100047483Abstract: The present invention provides a birefringent film having an index ellipsoid satisfying a relationship of nz>nx>ny, and having thinness and light weight, which can be relatively easily produced. The birefringent film of the present invention contains an acenaphtho[1,2-b]quinoxaline derivative represented by the following general formula (I), and an index ellipsoid of the film satisfies a relationship of nz>nx>ny. Here, in the formula (I), X, Y, and Z each independently represent a halogen atom, an alkoxy group, an —R group, an —OM group, a —COOM group, an —OCOR group, an —NHCOR group, a —CONHR group, an —NH2 group, an —NO2 group, a —CF3 group, a —CN group, an —OCN group, an —SCN group, an —SM group, and a —PO3M group; M represents a counterion; R represents hydrocarbon; k, l, m, and n represent the number of substitutions, k is an integer of 1 to 4, and l, m and n are each independently an integer of 0 to 3.Type: ApplicationFiled: March 3, 2008Publication date: February 25, 2010Applicant: NITTO DENKO CORPORATIONInventor: Shoichi Matsuda
-
Patent number: 7662487Abstract: The invention aims at providing a novel azaaromatic compound having an azafluoranthene skeleton which is useful as the constituent of organic EL devices and at realizing a long lifetime, high-efficiency and practical organic EL device by using the compound in at least one of the organic compound layers.Type: GrantFiled: October 31, 2007Date of Patent: February 16, 2010Assignee: Idemitsu Kosan Co., Ltd.Inventor: Toshihiro Iwakuma
-
Publication number: 20090325971Abstract: The present invention relates to Pentacyclic Alkaloid Compounds, compositions comprising an effective amount of a Pentacyclic Alkaloid Compound and methods for treating or preventing cancer, a bacterial infection, a fungal infection, or a yeast infection, comprising administering to a subject in need thereof an effective amount of a Pentacyclic Alkaloid Compound. The present invention also relates to compounds and methods that are useful for making Cribrostatin IV.Type: ApplicationFiled: February 28, 2006Publication date: December 31, 2009Applicant: The Trustees Of Columbia University In The City Of New YorkInventors: Samuel J. Danishefsky, Collin Chan
-
Publication number: 20090318421Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.Type: ApplicationFiled: April 28, 2006Publication date: December 24, 2009Inventors: Brian Alvin Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
-
Publication number: 20090315022Abstract: An azaindenofluorenedione derivative shown by the following formula (I), (IIa) or (IIb):Type: ApplicationFiled: November 28, 2008Publication date: December 24, 2009Applicant: Idemitsu Kosan Co., Ltd.Inventors: Hironobu MORISHITA, Yuichiro KAWAMURA
-
Publication number: 20090269846Abstract: The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised by the database, and identifying one or more high-scoring compounds. The methods further comprise testing a compound for RTK inhibitory activity in vitro, and testing a compound for specificity as an RTK inhibitor. Also disclosed are compounds selected by the described methods, and methods of treatment using the compounds. Two compounds (NSC11241 and NSC56452) are disclosed that inhibit EGF receptor kinase activation in a dose-dependent manner.Type: ApplicationFiled: April 6, 2009Publication date: October 29, 2009Applicant: Washington UniversityInventors: Garland R. Marshall, Linda J. Pike, Robert Yang
-
Publication number: 20090243476Abstract: An acenaphthoquinoxaline derivative represented by a general formula (G1) is provided. The acenaphthoquinoxaline derivative represented by the general formula (G1) easily receives electrons and has an electron-transporting property. Therefore, the acenaphthoquinoxaline derivative can be suitably used for a light-emitting element.Type: ApplicationFiled: March 20, 2009Publication date: October 1, 2009Inventors: Ryoji Nomura, Takako Takasu, Satoko Shitagaki, Tsunenori Suzuki, Satoshi Seo
-
Publication number: 20090197065Abstract: A birefringent film of the present invention comprises at least one kind of polycyclic compound including a —COOM group (the M denotes a counter ion), wherein an index ellipsoid satisfies a relation of nz>nx=ny. The polycyclic compound includes, for example, acenaphtho[1,2-b]quinoxaline derivative represented by the following general formula (I). The birefringent film of the present invention can be formed thin-type and have a high birefringent index in the thickness direction, since the birefringent film comprises the polycyclic compound.Type: ApplicationFiled: May 17, 2007Publication date: August 6, 2009Applicant: NITTO DENKO CORPORATIONInventors: Junzo Miyazaki, Shoichi Matsuda, Tatsuki Nagatsuka
-
Publication number: 20090191394Abstract: The present invention is related to the synthesis of acenaphthoquinoxaline sulfonamide derivatives and the manufacture of optical crystal films based on these compounds. Said acenaphthoquinoxaline sulfonamide heterocyclic derivatives have the general structural formula: where n is 1, 2 or 3; X is an acid group; m is 1, 2 or 3; Y is a counterion selected from the list consisting of H+, NH4+, Na+, K+, and Li+; p is the number of counterions providing neutral state of the molecule; R is a substituent selected from the list consisting of —CH3, —C2H5, —NO2, —Cl, —Br, —F, —CF3, —CN, —OH —OCH3, —OC2H5, —OCOCH3, —OCN, —SCN, —NH2, —NHCOCH3, —CONH2; and z is 1, 2, 3 or 4.Type: ApplicationFiled: October 9, 2006Publication date: July 30, 2009Inventors: Pavel I. Lazarev, Elena N. Sidorenko
-
Publication number: 20090167167Abstract: Disclosed is a novel compound useful as a constituent of an organic EL device. Also disclosed is a practical organic EL device using this compound. This organic EL device has low driving voltage, long life, and reduced leakage current. Specifically disclosed is a compound characterized by having at least one structure (1) shown below in a molecule.Type: ApplicationFiled: December 5, 2008Publication date: July 2, 2009Applicants: Idemitsu Kosan Co., Ltd., Sony CorporationInventors: Yoshiaki Aoyama, Hironobu Morishita, Chishio Hosokawa, Shigeyuki Matsunami, Yasunori Kijima
-
Patent number: 7524956Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.Type: GrantFiled: July 9, 2007Date of Patent: April 28, 2009Assignee: Pharma Mar, S.A.Inventors: Carmen Cuevas, Marta Perez, Andres Francesch, Carolina Fernandez, Jose Luis Chicharro, Pilar Gallego, Maria Zarzuelo, Fernando de Calle, Ignacio Manzanares
-
Publication number: 20090105447Abstract: The present invention relates to polymers comprising a repeating unit of the formula (I), and their use in electronic devices. The polymers according to the invention have excellent 5 solubility in organic solvents and excellent film-forming properties. In addition, high charge carrier mobilities and high temperature stability of the emission color are observed, if the polymers according to the invention are used in polymer light emitting diodes (PLEDs).Type: ApplicationFiled: March 8, 2006Publication date: April 23, 2009Inventors: Thomas Schafer, Beat Schmidhalter, Peter Murer, Kristina Bardon, Tobias Hintermann
-
Patent number: 7517476Abstract: A polymer represented by Formula or structure (I) wherein at least one of each R, R1, R2, R3, R4, R5, and R6 is independently hydrogen, alkyl, aryl, arylalkyl, alkoxy, halogen, cyano, or nitro; x, y, a and b represent the number of groups and rings, respectively; and n represents the number of repeating groups or moieties.Type: GrantFiled: April 6, 2006Date of Patent: April 14, 2009Assignee: Xerox CorporationInventors: Yiliang Wu, Ping Liu, Beng S. Ong
-
Patent number: 7517477Abstract: An electronic device, such as a thin film transistor, containing a polymer of the formula or structure wherein at least one of each R, R1, R2, R3, R4, R5 and R6 is independently hydrogen, alkyl, aryl, alkoxy, halogen, arylalkyl, cyano, or nitro; x and y represent the number of R substituents; a and b represent the number of rings; and n represents the number of repeating groups or moieties.Type: GrantFiled: April 6, 2006Date of Patent: April 14, 2009Assignee: Xerox CorporationInventors: Yiliang Wu, Ping Liu, Beng S. Ong
-
Patent number: 7517883Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.Type: GrantFiled: August 24, 2005Date of Patent: April 14, 2009Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
-
Publication number: 20090023721Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.Type: ApplicationFiled: May 24, 2006Publication date: January 22, 2009Inventors: Antonius Adrianus Hendrikus Petrus Megens, Andres Avelino Trabanco-Suarez, Jose Maria Cid-Nunez, Hua Mao, Sushil Chandra Jha, Francisco Javier Fernandez-Gadea, Mohamed Koukni, Georges Joseph Cornelius Hoornaert, Frans Josef Cornelius Compernolle, Tomasz Kozlecki
-
Patent number: 7468366Abstract: The invention provides compounds of the invention pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.Type: GrantFiled: December 12, 2007Date of Patent: December 23, 2008Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman, Sudhir K. Singh, Abhijit Ray, Leroy F. Liu
-
Publication number: 20080305082Abstract: Disclosed are compounds having Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, A, and B are as defined herein, for use in methods for treating, preventing or ameliorating hyperproliferative disorders, such as cancer and other diseases and conditions. The invention also relates to pharmaceutical compositions and formulations comprising a compound having Formula I, and in combination with one or more other active agents and/or treatments.Type: ApplicationFiled: September 14, 2005Publication date: December 11, 2008Inventors: John G. Curd, Robert L. Capizzi, John F.W. Keana
-
Publication number: 20080287450Abstract: This invention concerns novel substituted tetracyclic tetrahydrofuran, pyrrolidine and tetrahydrothiophene derivatives with binding affinities towards serotonin receptors, in particular 5-HT2A and 5-HT2C receptors, and towards dopamine receptors, in particular dopamine D2 receptors and with norepinephrine reuptake inhibition properties, pharmaceutical compositions comprising the compounds according to the invention, the use thereof as a medicine, in particular for the prevention and/or treatment of a range of psychiatric and neurological disorders, in particular certain psychotic, cardiovascular and gastrokinetic disorders and processes for their production. The compounds according to the invention can be represented by general Formula (I) and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim 1.Type: ApplicationFiled: December 6, 2005Publication date: November 20, 2008Inventors: Jose Maria Cid-Nunez, Antonius Adrianus Hendrikus Petrus Megens, Andres Avelino Trabanco-Suarez, Mohamed Koukni, Georges Joseph Cornelius Hoornaert, Frans Josef Cornelius Compernolle, Tomasz Kozlecki, Hua Mao, Sushil Chandra Jha, Francisco Javier Fernandez-Gadea
-
Publication number: 20080224095Abstract: The present invention provides a birefringent film that hardly generates cracks even when the film is exposed under a high-temperature and high-humidity environment for a long period of time. The birefringent film of the present invention is a film containing, as a major component, a lyotropic liquid crystalline polycyclic compound containing an acenaphtho[1,2-b]quinoxaline derivative unit in a molecular structure and having a molecular weight of 500 or higher. The birefringent film of the present invention preferably has a refractive index ellipsoid showing a relationship of nx?nz>ny, and more preferably has an in-plane birefringence of 0.01 or higher at the wavelength of 590 nm.Type: ApplicationFiled: March 17, 2008Publication date: September 18, 2008Applicant: NITTO DENKO CORPORATIONInventors: Shoichi MATSUDA, Junzo MIYAZAKI
-
Publication number: 20080206597Abstract: The invention aims at providing a novel azaaromatic compound having an azafluoranthene skeleton which is useful as the constituent of organic EL devices and at realizing a long lifetime, high-efficiency and practical organic EL device by using the compound in at least one of the organic compound layers.Type: ApplicationFiled: October 31, 2007Publication date: August 28, 2008Applicant: Idemitsu Kosan Co., Ltd.Inventor: Toshihiro IWAKUMA
-
Patent number: 7417145Abstract: An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R2 of N12 site is trichloroethoxicarbonyl (Troc) to which various substituents can be introduced by mild condition, further having a 10-membered ring structure which can be converted to a ring of other numbered members.Type: GrantFiled: September 20, 2002Date of Patent: August 26, 2008Assignee: Japan Science and Technology AgencyInventors: Tohru Fukuyama, Toshiyuki Kan
-
Publication number: 20080121873Abstract: An objective is to provide an organic thin film transistor material exhibiting an excellent property as a transistor together with reduced aging degradation, and also to provide an organic thin film transistor, a field-effect transistor, a switching element, an organic semiconductor material and an organic semiconductor film employing the organic thin film transistor material. Disclosed is an organic thin film transistor material possessing a compound represented by the following Formula (1). where A composed of a condensed ring formed with a 6 membered aromatic cycle or a 6 membered aromatic heterocycle represents C—R, N or P; at least one of As is N or P; R represents a hydrogen atom, a halogen atom or a substituent; and R may be bonded with other Rs with each other to form a ring.Type: ApplicationFiled: November 17, 2005Publication date: May 29, 2008Applicant: KONICA MINOLTA HOLDINGS, INC.Inventors: Rie Katakura, Hiroshi Kita, Katsura Hirai, Tatsuo Tanaka
-
Patent number: 7345172Abstract: In accordance with the present invention there is provided a new class of sterically demanding metallo-intercalators. These compounds intercalate between bases in a duplex polynucleotide, but only where the bases are not fully complementary, for example, where there is a base-pair mismatch. The compounds are sufficiently sterically demanding that intercalation between bases in fully complementary duplexes does not occur to a significant degree. These mismatch intercalators are useful for detecting DNA and RNA defects, for diagnosing disorders characterized by the presence or increase in DNA and/or RNA defects, and for treating such disorders. Further, the compounds are capable of catalyzing photolytic cleavage of nucleic acids at relatively long wavelengths, and under normal sunlight.Type: GrantFiled: October 26, 2004Date of Patent: March 18, 2008Assignee: Calfornia Institute of TechnologyInventors: Jacqueline K. Barton, Henrik Junicke
-
Patent number: 7338553Abstract: A process for printing an image on a substrate comprising applying to the substrate an ink comprising a compound of Formula (1) or a salt thereof: wherein: R1 and R2 are each independently H or a substituent; each X and Y independently is a substituent; and a and b are each independently 0, 1, 2, 3 or 4. The compounds used in the process have particularly good ozone fastness and are suitable for preparing inks which can be ink jet printed.Type: GrantFiled: September 21, 2006Date of Patent: March 4, 2008Assignee: Fujifilm Imaging Colorants LimitedInventor: Clive Edwin Foster
-
Patent number: 7319105Abstract: The invention provides compounds of the invention pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.Type: GrantFiled: May 14, 2004Date of Patent: January 15, 2008Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman, Sudhir K. Singh, Abhijit Ray, Leroy F. Liu
-
Patent number: 7241892Abstract: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically: R1 is an amidomethylene group or an acyloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.Type: GrantFiled: May 15, 2000Date of Patent: July 10, 2007Assignee: Pharma Mar, S.A.Inventors: Carmen Cuevas, Marta Perez, Andres Francesch, Carolina Fernandez, Jose Luis Chicharro, Pilar Gallego, Maria Zarzuelo, Fernando de la Calle, Ignacio Manzanares
-
Patent number: 7144608Abstract: A color-correcting polarizer is provided comprising a polarizer layer and at least one discotic film layer. The discotic film layer is optically transparent within the range of visible wavelength. The discotic film layer works as a polarizer in the wavelength ranges at least from 380 to 500 nm and/or from 600 to 780 nm. A liquid crystal cell comprising the color correcting polarizer is also disclosed.Type: GrantFiled: June 18, 2003Date of Patent: December 5, 2006Assignee: Nitto Denko CorporationInventors: Michael V. Paukshto, Louis D. Silverstein
-
Patent number: 7122549Abstract: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.Type: GrantFiled: April 16, 2004Date of Patent: October 17, 2006Assignee: President and Fellows of Harvard CollegeInventors: Andrew G. Myers, Alleyn T. Plowright
-
Patent number: 7098209Abstract: Compounds of the general structural formula (I), and use of the compounds and salts and solvates thereof, as thereapeutic agents.Type: GrantFiled: April 15, 2002Date of Patent: August 29, 2006Assignee: Lilly Icos LLCInventors: Mark W. Orme, Jason S. Sawyer, Lisa M. Schultze
-
Patent number: 7049315Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.Type: GrantFiled: May 14, 2004Date of Patent: May 23, 2006Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman, Leroy F. Liu
-
Patent number: 7045177Abstract: The present invention provides a series of new chemical compounds, lyotropic liquid crystal systems, materials, blends, mixtures, namely acenaphtho[1,2-b]quinoxaline sulfoderivatives of the general structural formula: wherein n is an integer in the range of 1 to 4; m is an integer in the range of 0 to 4; z is an integer in the range of 0 to 6, and m+z+n?10; X and Y are individually selected from the group consisting of CH3, C2H5, OCH3, OC2H5, Cl, Br, OH, OCOCH3NH2, NHCOCH3, NO2, F, CF3, CN, OCN, SCN, COOH, and CONH2; M is a counterion; and j is the number of counterions in the molecule.Type: GrantFiled: November 17, 2004Date of Patent: May 16, 2006Assignee: Nitto Denko CorporationInventors: Tatyana Y. Dutova, Alexey Y. Nokel, Elena N. Sidorenko, Sergey V. Timofeev
-
Patent number: 6987109Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.Type: GrantFiled: May 14, 2004Date of Patent: January 17, 2006Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman
-
Patent number: 6982333Abstract: The present invention provides a short, convergent total synthesis of camptothecin and related compounds which consists of a novel 4+1 radical annulation. The present invention also provides novel chemical intermediates for such 4+1 radical annulations.Type: GrantFiled: September 16, 2003Date of Patent: January 3, 2006Assignee: University of PittsburghInventors: Dennis P. Curran, Hubert Josien, Sung Bo Ko
-
Patent number: 6964964Abstract: The invention provides compounds of formula I: wherein A, B, W, Y, Z, R1, R3 and R4 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.Type: GrantFiled: May 14, 2004Date of Patent: November 15, 2005Assignee: Rutgers The State University of New JerseyInventors: Edmond J. LaVoie, Alexander L. Ruchelman
-
Patent number: 6936714Abstract: Compounds of the saframycin-ecteinascidin series with cytotoxic properties having the following general formula, their uses and synthesis, are disclosed: wherein R1 and R4 is H, a C1 to C4 alkyl group, or an acyl group; wherein R2 is an ether, ester, amide, or a phthalimide group; wherein R3 is ?O, OH, an ether group, an acyl group such as OC(O)Me, OC(O)Bn and OC(O)Et, or a sulfide group; wherein R5 is H, halogen, OH, an ether group, an acyl group, or an amide group; wherein R6 is ?O, OH, OCH3, CN, or an acyloxy group; wherein R7, is ?O, OH, halogen, an ether group, or an acyl group; wherein R8 and R9 are independently H, CH3, OCH3, OC2H5, CF3, halogen such as Br and F, or R8 and R9 are joined together as a methylenedioxy group, or other five or six membered ring; wherein R10 and R11 are independently CH3, OCH3, OC2H5, SCH3, or SC2H5; wherein R12 is H, a C1 to C4 alkyl group, or an acyl group; and wherein the chiral center marked * has the R or the S configuration.Type: GrantFiled: December 5, 2003Date of Patent: August 30, 2005Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel J. Danishefsky, Bishan Zhou
-
Patent number: 6878711Abstract: Compounds of the general structural formula and use of the compounds and salts and solvates thereof, as therapeutic agents.Type: GrantFiled: October 9, 2001Date of Patent: April 12, 2005Assignee: Lilly Icos LLCInventors: Mark W. Orme, Jason Scott Sawyer, Lisa M. Schultze
-
Patent number: RE41614Abstract: The present invention is directed to the synthesis and characterization of compounds having the formula: wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from the group consisting of H, OH, OR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHC(?O)R? NHC(?O)R?, CN, halogen, ?O, C(?O)H, C(?O)R?, CO2H, CO2R?, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, and substituted or unsubstituted heteroaromatic; wherein each of the R? groups is independently selected from the group consisting of H, OH, NH2, NO2, SH, CN, halogen, ?O, C(?O)H, C(?O)CH3, CO2H, CO2CH3, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, aralkyl, and heteroaromatic; wherein each dotted circle represents one, two or three optional double bonds; wherein R7 and R8 may be are joined into a carbocyclic or heterocyclic ring system; and wherein X1 and X2 are each independently defined as above for R1-R8 R1-R6 and R9, and each further includes sType: GrantFiled: December 17, 2003Date of Patent: August 31, 2010Assignee: President and Fellows of Harvard CollegeInventor: Elias J. Corey